Ozempic vs Wegovy: Same Drug, Different Label

One of the most common sources of confusion in the whole GLP-1 conversation is that “Ozempic” and “Wegovy” get talked about as if they were rival drugs. They aren’t. Both are semaglutide, both are made by Novo Nordisk, and the active ingredient inside the pen is identical. What differs is the label on the box — and the label turns out to carry more practical weight than most people expect.

Salad, fresh, organic — illustrating Ozempic vs Wegovy: Same Drug, Different Label

Same molecule, different job

Semaglutide is a GLP-1 receptor agonist: it mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite through the brain. That single mechanism is doing the work in both products. The distinction is regulatory, not chemical.

Ozempic was approved by the FDA in 2017 for type 2 diabetes. It’s dosed weekly and titrated up to a maximum of 2.0 mg. In people with type 2 diabetes and established cardiovascular disease, it also carries an indication to reduce the risk of major cardiovascular events.
Wegovy was approved in 2021 for chronic weight management in adults with obesity (BMI ≥ 30), or overweight (BMI ≥ 27) with a weight-related condition. It titrates to a higher maximum — 2.4 mg weekly — and in 2024 also gained an indication to reduce cardiovascular risk in adults with established heart disease plus obesity or overweight, on the strength of the SELECT trial.

So the honest one-line summary: same drug, but Ozempic is the diabetes label and Wegovy is the obesity label, with Wegovy going to a higher top dose.

The differences that actually matter

	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
FDA approval	2017	2021
Primary indication	Type 2 diabetes	Chronic weight management
Maximum dose	2.0 mg / week	2.4 mg / week
Route	Weekly subcutaneous injection	Weekly subcutaneous injection
Cardiovascular indication	T2D + established CVD	Established CVD + obesity/overweight

The dose gap is small in absolute terms but relevant: Wegovy’s higher ceiling reflects that it was studied and titrated specifically for weight loss. The STEP program tested semaglutide 2.4 mg for obesity and reported average weight loss around 15% over 68 weeks — the number most people associate with “Wegovy.” Ozempic’s diabetes trials (the SUSTAIN program) were designed around glycemic control, with weight loss as a secondary benefit.

Because the drug is the same, the difference in results between “Ozempic for weight loss” and Wegovy comes down mostly to dose and titration — not to any special property of one product over the other.

Pumpkins, nature, pumpkin patch — illustrating Ozempic vs Wegovy: Same Drug, Different Label

Why coverage and supply muddy the picture

If the molecule is identical, why does anyone care which box it comes in? Money and access.

Insurance plans frequently cover Ozempic for diabetes but exclude Wegovy for weight loss, or vice versa, and prior-authorization rules differ. During the shortages of recent years, one product could be available while the other wasn’t. That’s a large part of why “using Ozempic for weight loss” became a phenomenon: people were prescribed the diabetes label off-label when the obesity label was unavailable or uncovered. It’s the same semaglutide either way — but the paperwork, the price, and the supply can diverge sharply.

Flax seed, seeds, eat — illustrating Ozempic vs Wegovy: Same Drug, Different Label

Where Rybelsus fits

There’s a third semaglutide worth naming so it doesn’t add to the confusion: Rybelsus, an oral tablet approved for type 2 diabetes. It’s the same active ingredient in pill form, taken daily on an empty stomach, with somewhat lower bioavailability than the injection. An oral version studied at higher doses for weight management has been under review as well. If you see “semaglutide” attached to three different names, this is why.

The takeaway

Ozempic and Wegovy are not competitors — they’re the same semaglutide wearing two different labels for two different approved uses, at two slightly different maximum doses. The practical decision almost never turns on the molecule; it turns on what you’re being treated for, which dose your clinician is targeting, and what your insurance will actually pay for. As always, that’s a conversation for a prescriber who knows your history, not a choice to make from a headline.